Difference 18100000 exceeds tolerance 4681900.000. Presentation or filing-vintage differences need review.
Valuation, from the filing
| Public float | $12.20B | Market value of stock held by non-affiliates, as stated on the cover page for 2025-06-30 |
|---|---|---|
| Float per share | $122.72 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
| Float / net income | 21.5× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / revenue | 2.1× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / equity | 3.8× | A lower bound on the multiple, because affiliate holdings are excluded. |
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.
Valuation over time
21.5× earnings today, against a median of 18.8× across 10 years on record. Above its own history.
| Float measured | Public float | Float / net income | |
|---|---|---|---|
| 2025-06-30 | $12.20B | 21.5× | |
| 2024-06-30 | $8.50B | 18.7× | |
| 2023-06-30 | $6.70B | 19.0× | |
| 2022-06-30 | $5.50B | 20.3× | |
| 2021-06-30 | $7.60B | 18.4× | |
| 2020-06-30 | $6.00B | 21.1× | |
| 2019-06-30 | $6.20B | 17.3× | |
| 2018-06-30 | $6.60B | 22.6× | |
| 2017-06-30 | $4.70B | 17.3× | |
| 2016-06-30 | $3.30B | 13.3× |
Each float is paired with the fiscal year the filing that stated it covers. Only years where the company reported positive net income appear, because a multiple against a loss is not a multiple.
Encompass Health Corp (EHC) reported revenue of $5.94B and net income of $566.20M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Encompass Health Corp’s SEC filings, each linked to the filing it came from.
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.94B | $5.37B | $4.80B | $4.35B | $4.01B | $3.57B | $4.60B | $4.28B | $3.91B | $3.64B |
| Cost of revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross profit | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating income | Unavailable | Unavailable | Unavailable | $539.50M | $559.60M | $563.90M | $612.10M | $555.20M | $578.30M | $588.10M |
| Net income | $566.20M | $455.70M | $352.00M | $271.00M | $412.20M | $284.20M | $358.70M | $292.30M | $271.10M | $247.60M |
| Research & development | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Weighted-average diluted shares | shares 102.20M | shares 102.20M | shares 101.30M | shares 100.40M | shares 100.20M | shares 99.80M | shares 99.40M | shares 99.80M | shares 99.30M | shares 99.50M |
| Pretax income | $953.00M | $749.60M | $607.20M | $450.80M | $505.00M | $352.90M | $562.30M | $493.20M | $496.40M | $482.00M |
| Income tax expense | $192.90M | $150.20M | $132.20M | $100.10M | $101.90M | $74.70M | $115.90M | $118.90M | $145.80M | $163.90M |
| Diluted EPS | $5.54 | $4.46 | $3.47 | $2.70 | $4.11 | $2.85 | $3.61 | $2.93 | $2.84 | $2.59 |
| Selling, general & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| General & administrative | $236.20M | $209.20M | $201.70M | $154.30M | $169.50M | $151.60M | $247.00M | $220.20M | $171.70M | $133.40M |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $72.20M | $85.40M | $69.10M | $21.80M | $49.40M | $185.60M | $60.00M | $69.20M | $54.40M | $40.50M |
| Total assets | $7.09B | $6.53B | $6.10B | $5.64B | $6.86B | $6.45B | $6.08B | $5.18B | $4.86B | $4.68B |
| Current assets | $905.90M | $886.90M | $841.80M | $717.20M | $921.40M | $948.60M | $755.80M | $662.10M | $702.20M | $654.50M |
| Total liabilities | $3.81B | $3.69B | $3.81B | $3.77B | $4.47B | $4.44B | $4.15B | $3.36B | $3.25B | $3.61B |
| Current liabilities | $836.40M | $841.00M | $656.40M | $575.90M | $748.80M | $717.30M | $721.00M | $672.50M | $517.50M | $475.60M |
| Total equity incl. NCI | $3.22B | $2.79B | $2.26B | $1.83B | $2.36B | $1.97B | $1.69B | $1.56B | $1.40B | $910.60M |
| Temporary (mezzanine) equity | $58.30M | $56.50M | $42.00M | $35.60M | $42.20M | $31.60M | $239.60M | $261.70M | $220.90M | $138.30M |
| Inventory | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts receivable | $619.20M | $593.00M | $599.80M | $524.80M | $502.10M | $563.00M | $498.70M | $459.90M | $459.50M | $432.00M |
| Goodwill | $1.32B | $1.28B | $1.28B | $1.26B | $1.24B | $1.23B | $1.22B | $2.10B | $1.97B | $1.93B |
| Long-term debt | $2.45B | $2.36B | $2.69B | $2.74B | $3.24B | $3.25B | $3.02B | $2.48B | $2.55B | $2.98B |
| Accounts payable | $178.20M | $171.00M | $170.00M | $132.90M | $134.00M | $115.00M | $94.60M | $90.00M | $78.40M | $68.30M |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | Unavailable | Unavailable | Unavailable | $705.80M | $715.80M | $704.70M | $635.30M | $762.40M | $658.30M | $640.20M |
| Capital expenditures | Unavailable | Unavailable | Unavailable | $564.80M | $524.60M | $392.80M | $372.40M | $254.50M | $225.80M | $177.70M |
| Investing cash flow | -$764.60M | -$653.30M | -$602.80M | -$627.00M | -$666.30M | -$407.50M | -$657.40M | -$424.50M | -$283.00M | -$229.90M |
| Financing cash flow | -$431.20M | -$330.60M | -$197.20M | -$145.70M | -$240.10M | -$145.90M | $48.20M | -$321.20M | -$359.90M | -$416.40M |
| Net change in cash | -$20.20M | $18.90M | $50.80M | -$66.90M | -$190.60M | $151.30M | $26.10M | $16.70M | $15.40M | -$6.10M |
| Stock-based compensation | $56.50M | $48.30M | $50.60M | $29.20M | $29.10M | $25.60M | $114.40M | $85.90M | $47.70M | $27.40M |
| Common dividends paid | $71.10M | $62.80M | $60.40M | $99.00M | $112.20M | $111.80M | $108.70M | $100.80M | $91.50M | $83.80M |
| Common share repurchases | $158.00M | $31.10M | $0 | $0 | $0 | $6.10M | $45.90M | $0 | $38.10M | $65.60M |
| Depreciation & amortization | $327.90M | $299.60M | $273.90M | $243.60M | $219.60M | $203.00M | $218.70M | $199.70M | $183.80M | $172.60M |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | Unavailable | Unavailable | Unavailable | $141.00M | $191.20M | $311.90M | $262.90M | $507.90M | $432.50M | $462.50M |
| Gross margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| FCF margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | 8.7% | 5.7% | 11.9% | 11.1% | 12.7% |
| SBC / revenue | 1.0% | 0.9% | 1.1% | 0.7% | 0.7% | 0.7% | 2.5% | 2.0% | 1.2% | 0.8% |
| Current ratio | 1.08x | 1.05x | 1.28x | 1.25x | 1.23x | 1.32x | 1.05x | 0.98x | 1.36x | 1.38x |
| Revenue YoY growth | 10.5% | 11.9% | 10.4% | 8.3% | 12.6% | -22.6% | 7.7% | 9.3% | 7.4% | Unavailable |
| Net margin | 9.5% | 8.5% | 7.3% | 6.2% | 10.3% | 8.0% | 7.8% | 6.8% | 6.9% | 6.8% |
| R&D / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| CapEx / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | 11.0% | 8.1% | 6.0% | 5.8% | 4.9% |
| Long-term debt / equity | 0.76x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 20.2% | 20.0% | 21.8% | 22.2% | 20.2% | 21.2% | 20.6% | 24.1% | 29.4% | 34.0% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open EHC in the interactive workspace to inspect any figure back to its filing.
Source filings
Companies in the same industry
Reconciliation checks needing review
1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.